Engineering insect cells increases tri-antennary N-glycan production, suggesting improvements for biopharmaceuticals.
Insect cells are attractive hosts for biopharmaceutical production due to their high productivity and mammalian-like post-translational modifications. However, their insect-specific N -glycans differ from mammalian types, thereby reducing product desirability. Here, with an emphasis on engineering N -glycosylation in insect cells, we aimed to develop a more tractable Spodoptera frugiperda Sf9 cell platform as a practical alternative to insect-based systems for engineering the production of tri-antennary N -glycans. A database search revealed that silkworm possesses N -acetylglucosaminyltransferase IV (GNTIV), a putative glycosyltransferase essential for tri-antennary N -glycan synthesis; however, it was not functional in vitro. Then, human GNTIV was introduced into insect cells, resulting in the production of small amounts of tri-antennary N -glycans. This suggested the need for additional factors to efficiently biosynthesize tri-antennary N -glycans. Subsequently, additional insect-derived glycosyltransferases, such as active GNTI and/or GNTII, were co-expressed with GNTIV. Co-expression of three N -acetylglucosaminyltransferases effectively led to the increased biosynthesis of tri-antennary N -glycans. On the other hand, trimming of the N -glycan structure was also observed due to the action of one or more endogenous glycosylhydrolases, which hydrolyze the terminal N -acetylglucosamine residue in insect cells. These facts indicate that effective tri-antennary N -glycan biosynthesis in insect cells requires not only the introduction of exogenous glycosyltransferases but also the knockdown or knockout of endogenous glycosylhydrolase(s).
No takes yet. Share an insight, caveat, or question.
Kajiura et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: